App-Quantinova.ai

CMET-19. QUESTIONING THE PARADIGM: DO CSF CYTOLOGY AND MRI SCANNING IDENTIFY THE SAME DISEASE IN PATIENTS WITH NEOPLASTIC MENINGITIS (NM) – DATA FROM AN INTERNATIONAL NM REGISTRY AND A META-ANALYSIS

Christopher Messner - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leptomeningeal Metastasis

N/A

EXTH-50. THIOREDOXIN REDUCTASE1 AND MGMT SYNTHETIC LETHALITY ENHANCES CYTOTOXICITY OF PRIMA-1MET(APR-246) AND AURANOFIN IN GLIOBLASTOMA

Rehka Raveendrakumar - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

buthionine sulfoximine

TMOD-02. A MODEL OF THE INITIATION AND GENOMIC LANDSCAPE OF GLIOBLASTOMA (GBM)

Kaitlin Thomas - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

EXTH-52. CO-TARGETING ONCOSTATIN M RECEPTOR USING MONOCLONAL ANTIBODIES IN COMBINATION WITH PRESENT STANDARDS OF CARE FOR GLIOBLASTOMA

Audrey Burban - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

CSIG-12. PREX1 LINKS ABERRANT PI 3-KINASE PATHWAY SIGNALING TO MAINTENANCE OF THE NEURAL STEM CELL-LIKE PHENOTYPE OF GLIOBLASTOMA CELLS

Ian Lorimer - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

CMET-25. COMPARATIVE EFFICACY OF TREATMENT PARADIGMS FOR BRAIN METASTASES – A SYSTEMATIC REVIEW

Karanbir Brar - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

GENE-40. CHARACTERIZING EPIGENETIC INTRATUMORAL HETEROGENEITY IN GLIOMA USING SINGLE-CELL BISULFITE SEQUENCING

Kevin C Johnson - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

EPID-09. PROGNOSTIC FACTORS IN ADULT PATIENTS WITH PRIMARY INTRACRANIAL EPENDYMOMAS: A POPULATION-BASED STUDY

Helen Yang - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ependymoma

N/A

SCIDOT-15. DISRUPTING THE BLOOD-BRAIN BARRIER IN NEURO-ONCOLOGY: INNOVATIONS, ACHIEVEMENTS, AND LESSONS LEARNED FROM CLINICAL TRIALS

Justine Philtheos - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

NCOG-03. COGNITIVE CONCERNS AND PERFORMANCE IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC)

Gary Rodin - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Non Small Cell Lung cancer

N/A

CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS

Yasin Mamatjan - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lung Cancer

N/A

PDTM-33. EUROPEAN GENETIC ANCESTRY ASSOCIATED WITH RISK OF CHILDHOOD EPENDYMOMA

Michael Taylor - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ependymoma

N/A

EPID-28. WHAT DO PATTERNS OF “UNCLASSIFIED” BRAIN TUMORS TELL US ABOUT INCIDENCE RATES OF NON-MALIGNANT BRAIN TUMORS IN CANADA?

Trenton Smith - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

STEM-21. INVESTIGATING DOT1L AS AN EPIGENETIC VULNERABILITY IN BRAIN TUMOR STEM CELLS

Danielle Bozek - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

Pinometostat

CMET-31. WHOLE BRAIN RADIOTHERAPY VERSUS STEREOTACTIC RADIOSURGERY IN POOR-PROGNOSIS PATIENTS WITH 1 – 10 BRAIN METASTASES: A RANDOMIZED FEASIBILITY STUDY

Alan Nichol - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

CSIG-22. REGULATION OF GLIOMA STEM CELL SELF-RENEWAL AND TUMORIGENESIS BY CARBOHYDRATE BINDING PROTEINS

Ahmad Sharanek - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

EGFRvIII

CMET-32. DNA METHYLATION ALTERATIONS IN LUNG ADENOCARCINOMAS THAT DEVELOP BRAIN METASTASES

Jeffrey Zuccato - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lung Cancer

N/A

Immunogenicity of new treatments: Current status of knowledge

D. Lillicrap - European Association for Haemophilia and Allied Disorders (EAHAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

NN7415

Inhibitor incidence in pups with severe haemophilia B is higher than usually reported; data from the PedNet registry

M. Van Den Berg - European Association for Haemophilia and Allied Disorders (EAHAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Perioperative management for patients with congenital factor XI deficiency

C. Chai-Adisaksopha - European Association for Haemophilia and Allied Disorders (EAHAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Hemostatic Solution

Filters

28841 Abstracts